GC Biopharma Corp. (KRX:006280)

GC Biopharma Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,934,378	1,679,892	1,626,644	1,711,313	1,537,826	1,504,115
Other Revenue	0	-	-0	-0	-0	-
Revenue	1,934,378	1,679,892	1,626,644	1,711,313	1,537,826	1,504,115
Revenue Growth (YoY)	17.66%	3.27%	-4.95%	11.28%	2.24%	10.83%
Cost of Revenue	1,400,459	1,199,348	1,143,313	1,131,350	1,018,585	1,064,691
Gross Profit	533,919	480,544	483,331	579,962	519,240	439,425
Selling, General & Admin	297,921	265,470	258,898	292,484	282,771	242,918
Research & Development	160,248	166,198	173,487	191,347	146,030	137,987
Amortization of Goodwill & Intangibles	9,323	6,695	4,985	3,856	2,087	1,524
Other Operating Expenses	1,359	1,277	1,624	2,165	1,594	1,259
Operating Expenses	480,886	448,505	449,420	499,253	445,515	389,239
Operating Income	53,033	32,039	33,911	80,710	73,726	50,186
Interest Expense	-47,910	-40,439	-28,483	-18,393	-12,501	-10,354
Interest & Investment Income	3,939	3,621	3,421	3,785	1,665	1,555
Earnings From Equity Investments	42,030	1,250	-	40,467	-	-
Currency Exchange Gain (Loss)	662	7,245	1,010	2,570	13,477	-17,517
Other Non Operating Income (Expenses)	-2,274	-1,440	3,147	-4,842	8,002	-913.65
EBT Excluding Unusual Items	49,480	2,276	13,006	104,296	84,368	22,956
Gain (Loss) on Sale of Investments	1,683	-20,799	-37,222	-18,759	81,200	31,038
Gain (Loss) on Sale of Assets	-2,992	-3,761	-2,919	190	6,991	58,619
Asset Writedown	-17,394	-18,088	-	-	-	-8,140
Other Unusual Items	-321	-738	-	-	-	-
Pretax Income	30,456	-41,110	-27,135	85,728	172,559	104,474
Income Tax Expense	-3,936	1,527	-7,326	16,313	35,609	15,366
Earnings From Continuing Operations	34,393	-42,637	-19,809	69,415	136,950	89,108
Earnings From Discontinued Operations	-	-	-	-	-	162.96
Net Income to Company	34,393	-42,637	-19,809	69,415	136,950	89,271
Minority Interest in Earnings	21,942	16,357	-6,823	-3,962	-13,738	-8,222
Net Income	56,335	-26,280	-26,632	65,453	123,212	81,049
Net Income to Common	56,335	-26,280	-26,632	65,453	123,212	81,049
Net Income Growth	-	-	-	-46.88%	52.02%	-
Shares Outstanding (Basic)	11	11	11	11	11	11
Shares Outstanding (Diluted)	11	11	11	11	11	11
Shares Change (YoY)	0.24%	-	-	-	-	-
EPS (Basic)	4929.94	-2302.62	-2333.42	5734.87	10795.57	7101.34
EPS (Diluted)	4929.94	-2302.62	-2333.42	5734.87	10795.57	7101.34
EPS Growth	-	-	-	-46.88%	52.02%	-
Free Cash Flow	36,082	-85,452	-84,560	61,158	23,658	-46,902
Free Cash Flow Per Share	3157.60	-7487.13	-7408.97	5358.56	2072.84	-4109.46
Dividend Per Share	1500.000	1500.000	-	-	-	-
Gross Margin	27.60%	28.61%	29.71%	33.89%	33.77%	29.22%
Operating Margin	2.74%	1.91%	2.08%	4.72%	4.79%	3.34%
Profit Margin	2.91%	-1.56%	-1.64%	3.82%	8.01%	5.39%
Free Cash Flow Margin	1.86%	-5.09%	-5.20%	3.57%	1.54%	-3.12%
EBITDA	141,161	113,074	109,810	145,806	129,630	98,977
EBITDA Margin	7.30%	6.73%	6.75%	8.52%	8.43%	6.58%
D&A For EBITDA	88,128	81,034	75,899	65,096	55,904	48,791
EBIT	53,033	32,039	33,911	80,710	73,726	50,186
EBIT Margin	2.74%	1.91%	2.08%	4.72%	4.79%	3.34%
Effective Tax Rate	-	-	-	19.03%	20.64%	14.71%
Advertising Expenses	-	35,238	40,739	50,726	49,015	39,770

Source: S&P Global Market Intelligence. Standard template. Financial Sources.